Rocket Lab's Split Personality: Institutional Faith Meets a Market That's Looking the Other Way

Rocket Lab's stock drops 18% amid Neutron delay and Iridium acquisition concerns, even as contracts and institutional buying continue.

There's a peculiar disconnect playing out in Rocket Lab's stock right now. The company is signing contracts faster than it can launch rockets, institutional money is quietly trickling in, and yet the share price keeps sliding as if none of it matters.

The latest vote of confidence came from IEQ Capital LLC, which acquired Rocket Lab shares worth $2.59 million, according to a filing made public on Monday. The timing is notable: the stock has shed 18.0 percent since the company disclosed a delay to its Neutron rocket's debut roughly two weeks ago, and it now trades 18 percent below its 50-day moving average of 70.02 euros.

The Neutron Problem Won't Go Away

The root of the market's unease can be summed up in a single word: Neutron. Rocket Lab's reusable launch vehicle — standing 141 feet tall and powered by Archimedes engines — was supposed to be the proof that the company had outgrown its niche as a builder of small Electron rockets. Instead, a fuel tank ruptured during a January test in Wallops, Virginia, pushing the first launch from an initial target of the first quarter of 2026 to no earlier than the fourth quarter.

CEO Peter Beck has responded by shifting the narrative. Rather than asking investors to pin their hopes on a single debut flight, he's now directing attention to the tenth Neutron launch — a subtle but telling pivot from the risk of a maiden voyage to the promise of a reliable cadence.

Whether that reframing lands with shareholders remains an open question. The core business, meanwhile, keeps humming along. The 93rd Electron mission is on the books, with nine further launches contracted through 2030. Just this past weekend, Rocket Lab sent an iQPS radar satellite for a Japanese customer from its New Zealand pad — the ninth successful iQPS mission for the company — arriving a day after the Iridium acquisition news broke.

An $8 Billion Bet on Iridium

That acquisition is the second major storyline. The $8 billion cash-and-stock deal for Iridium Communications, featuring a $27-per-share cash component, goes to a shareholder vote on September 24. For a company still needing to prove Neutron can fly, taking on a deal of this magnitude is a leveraged gamble — analysts at Seeking Alpha have already flagged rising debt and slapped a Sell rating on the stock.

The financing picture adds another layer of complexity. On August 13, Rocket Lab signed a new equity distribution agreement with Deutsche Bank Securities and Wells Fargo Securities, permitting the sale of its own shares worth up to $1,944,369,826. The company says no additional shares will be issued beyond the unplaced amount from the prior program, but the arrangement keeps the dilution debate alive at a moment when investors are already skittish.

The SpaceX Gravity Well

Then there's the elephant that isn't really about Rocket Lab at all but shapes every move in the sector: SpaceX. Since the competitor's public listing, it has been sucking up much of the attention and capital flowing into space stocks. With a market capitalization of $1.8 trillion and plans for a $100 billion launch facility in Louisiana, SpaceX makes Rocket Lab look almost modest by comparison — despite the latter's record numbers.

The second-quarter results were, by any normal measure, impressive. Revenue climbed 62 percent to $234 million, and the backlog swelled to $2.36 billion. New orders exceeding $1 billion landed in the quarter alone, including the NITE-STAR program worth up to $981 million, a Flatellite contract valued at $397 million, and a missile-defense deal at $266 million. That's the kind of growth that growth stocks are supposed to be rewarded for.

Rocket Lab wasn't. The stock closed Tuesday at 57.50 euros, down 1.9 percent on the day and 11 percent over seven days. The gap to its 52-week high stands at a painful 57 percent. Anyone who bought in May is sitting on one of the more bruising losses in the entire space and defense complex.

Signals in Both Directions

The satellite business for third parties is also advancing. On August 15, satellite platforms Rocket Lab built for MDA Space reached orbit successfully, supporting Globalstar's direct-to-device communication services. The company said those were the first eight of 17 platforms from a $143 million contract — evidence that the diversified model works beyond the launch pad.

Yet the insider activity tells a different story. Over the past six months, insiders sold shares worth $329 million across 106 transactions — a signal that shouldn't be overinterpreted but also can't be ignored.

Analysts at Simply Wall St peg the fair value of the stock at $85.04, implying upside of roughly a fifth from the recent price of $66.91. The broader analyst consensus is even more bullish, with a median price target of $120.

The IEQ Capital purchase suggests at least some institutional players are weighing the operational substance — the iQPS series, the MDA Space business, the growing backlog — more heavily than the near-term uncertainty around Neutron's timeline. For everyone else, the summer's defining question remains whether that fundamental strength can eventually outweigh the combined drag of dilution risk, launch delays, and the gravitational pull of a much larger rival. The answer likely won't arrive until Neutron actually lifts off — and until shareholders cast their votes on Iridium in September.